NCT01335295已完成1 期
Open Pilot Trial to Test the Safety and Tolerability of Flavocoxid in Duchenne Muscular Dystrophy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- All adverse events and laboratory or ECG abnormalities
研究概览
简要总结
Objective of this study is to evaluate safety and tolerability of flavocoxid administered at the daily oral dose of 500 or 1000 mg/die for one year in DMD patients, alone or in association with steroids (deflazacort on alternate days) started at least one year before. The investigators will also perform a multidimensional clinical evaluation covering functional and muscle strength and quality of life (QoL)assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 16 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •clinical diagnosis of DMD, confirmed by muscle biopsy and molecular analysis by MPLA;
- •range of age between 4 -16 years;
- •unaided ambulation for at least 75 meters, unassisted during the Screening 6MWT. Other personal assistance or use of assistive devices for ambulation (eg, short leg braces, long leg braces or walkers) is not permitted.
- •follow-up of at least 1 year before baseline with the selected motor outcome measures;
- •patients able to perform evaluation tests;
- •patient legally authorized representative (LAR) able to understand and give the informed consent;
- •absence of contra-indications to the use of flavocoxid (see below);
- •written informed consent signed by LAR.
排除标准
- •treatment with other drugs analogue, similar or interacting with flavocoxid or immunosuppressive therapy (other than corticosteroids) within 3 months prior to start of study treatment;
- •exposure to another investigational drug or supplements within 2 months prior to start of study treatment;
- •presence of cognitive impairment that could influence the performance of the evaluation tests;
- •history of major surgical procedure within 30 days prior to start of study treatment;
- •expectation of major surgical procedure (eg, scoliosis surgery) during the 12-month treatment period of the study;
- •ongoing participation in any other therapeutic clinical study;
- •expectation of recruitment in the forthcoming exon-51 trial;
- •requirement for daytime ventilator assistance;
- •presence of liver-diseases or assumption of any hepatotoxic agent;
- •screening laboratory values out of the laboratory ranges if clinically meaningful;
- •prior or ongoing medical condition (eg, concomitant illness, psychiatric condition, behavioral disorder, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
结局指标
主要结局
All adverse events and laboratory or ECG abnormalities
时间窗: 1 year
次要结局
- Motor assessments and biochemical evaluation(1 year)
研究者
Giuseppe Vita
full professor
University of Messina
研究点 (2)
Loading locations...
相似试验
已完成
1 期
An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy VolunteersHealthy VolunteerNCT03205462Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation25
已完成
1 期
MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT03489525MedImmune LLC107
已完成
2 期
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)HCVChronic Hepatitis C InfectionHepatitis C Genotype 1Hepatitis CNCT01221298AbbVie (prior sponsor, Abbott)11
进行中（未招募）
1 期
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsHepatocellular CarcinomaNCT06239155Ascentawits Pharmaceuticals, Ltd51
已完成
1 期
Phase I Study on VEGF Vaccination in Metastatic Solid TumorsMetastatic CancerNCT02237638Amsterdam UMC, location VUmc30